FDA Slams Viibryd: Better Sexual Profile Claim “Not Supported by the Data” The Carlat Psychiatry Blog by Danny Carlat October 26, 2011 The September 2011 issue of the Journal of Clinical Psychiatry created history in two ways. First, the journal published this article written by FDA staff critically reviewing the efficacy and safety data of […]
After the second email about the female suicide statistics, I gave in to the temptation and parsed out the age groups so they could be seen more clearly. First, the spaghetti, then the deconstructed version: Here, for comparison, are the men [again note the y-axis scale differences between men and women]: I don’t know what […]
When I was looking around at the data in the last post [tortured numbers…], I ran into the CDC Compressed Mortality database for the first time. I stuck to the 1999 – 2007 version to reproduce the results in the NBER article I was reviewing, but I noticed that there was a second version from […]
Abbott Said to Agree to Pay $1.3 Billion for Depakote Suits Bloomberg By Jef Feeley and Margaret Cronin Fisk Oct 21, 2011 Abbott Laboratories agreed to pay at least $1.3 billion to settle claims by the U.S. government and 24 states alleging the company illegally marketed its Depakote epilepsy drug, people familiar with the accords […]
I am pleased that Dr. Allen Frances has taken up this particular fight. I would never have predicted that he would be the one, but that makes it all the more hopeful. I gave up on the APA [American Psychiatric Association] so long ago that I’ve forgotten when it happened. It just seemed like there […]
I said previously that I wasn’t going to argue with this FDA warning business [pretty loud coi…]. I should never say such a thing, because when I started peeping into the volumes written about this controversy, I got captured. So I take it back. Here comes some more of one piece of this story – […]
Since the post I want too talk about on Pharmalot comes from an article from the National Bureau of Economic Research, you might get a handle on who they are before proceeding: National Bureau of Economic Research Sourcewatch accessed 10/24/2011 A December 1, 2002, news story in the New York Times on the National Bureau […]
In nosing around about Paxil Withdrawal, I looked in PubMed for Author [Nemeroff + Schatzberg] – just wondering when they got to be such pals, and I ran across this article [full text on-line]. This article was accepted for publication in May 2006. At the time, Dr. Nemeroff was Chairman of Psychiatry at Emory and […]
Paxil ad from 2001 Paxil ad from 2002 I just received a copy of a GSK Press Release from 2002, obviously published in response to the ruling in the last post. It speaks to a lot of things, but the central point is how corrupt things had become by then. They still had four years […]
Paxil came on the scene in 1992, heavily advertised as the better Prozac. As pharmaceutical marketing misbehavior goes, GSK‘s Paxil ranks near the top of the list – well described in the must-read book, Side Effects: A Prosecutor, a Whistleblower, and a Bestselling Antidepressant on Trial, by Alison Bass. It had all the elements of […]